The Radiation Oncology Section of Johns Hopkins seeks research support for participation in the Radiation Therapy Oncology Group, a national cooperative group involved in improving oncologic therapy through clinical investigation. Commitment to these extensive and thorough investigative efforts by Johns Hopkins includes cooperative trials, data collection and recording, initiation of protocol design, and leadership of the RTOG Committee on Radioimmunoglobulin. Johns Hopkins Radiation Therapy clinical services has been an active RTOG member and to further participate and contribute to the RTOG cooperative trials seeks research support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA029536-07
Application #
3557093
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-05-01
Project End
1989-03-31
Budget Start
1987-04-01
Budget End
1988-03-31
Support Year
7
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Stillwagon, G B; Order, S E; Guse, C et al. (1991) Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01. Int J Radiat Oncol Biol Phys 20:65-71
Order, S; Pajak, T; Leibel, S et al. (1991) A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 20:953-63
Vriesendorp, H M; Herpst, J M; Leichner, P K et al. (1989) Polyclonal 90Yttrium labeled antiferritin for refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 17:815-21
Order, S E; Sleeper, A M; Stillwagon, G B et al. (1989) Current status of radioimmunoglobulins in the treatment of human malignancy. Oncology (Williston Park) 3:115-20;discussion 122, 129-30
Order, S E; Sleeper, A M; Stillwagon, G B et al. (1989) Current status of radioimmunoglobulins in the treatment of human malignancy. Oncology (Williston Park) 3:115-20;discussion 122, 129-30
Lee, D J; Pajak, T F; Stetz, J et al. (1989) A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). Int J Radiat Oncol Biol Phys 16:465-70
Order, S E; Klein, J L; Leichner, P K (1987) Hepatoma: model for radiolabeled antibody in cancer treatment. NCI Monogr :7-41
Order, S E; Klein, J L; Leichner, P K et al. (1986) Radiolabeled antibody in the treatment of primary and metastatic liver malignancies. Recent Results Cancer Res 100:307-14
Klein, J L; Sandoz, J W; Kopher, K A et al. (1986) Detection of specific anti-antibodies in patients treated with radiolabeled antibody. Int J Radiat Oncol Biol Phys 12:939-43
Order, S E; Stillwagon, G B; Klein, J L et al. (1985) Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study. J Clin Oncol 3:1573-82

Showing the most recent 10 out of 12 publications